Sibiriline - SeaBeLife Biotech
Alternative Names: SBL-01Latest Information Update: 22 Sep 2024
At a glance
- Originator SeaBeLife
- Class Hepatoprotectants; Small molecules
- Mechanism of Action Necroptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders
Most Recent Events
- 14 Aug 2024 SeaBeLife Biotech has patent protection for ferroptosis/necroptosis inhibitors prior to August 2024 (SeaBeLife Biotech website; August 2024)
- 05 Jun 2024 Preclinical trials in Liver disorders in France (IV) prior to June 2024
- 05 Jun 2024 Pharmacodynamic data from the preclinical trial in liver disorders presented at the European Association for the Study of the Liver Congress 2024 (EASL 2024)